Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 299

1.

Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial.

Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W, Xu M, Zhong P, Yu S, Chen D, Ding X, Zhang Y, Zheng X, Yang J, Qian J, Deng Y, Hoon DSB, Hu J, Chu Y, Zhou L.

Cancer Immunol Immunother. 2018 Aug 22. doi: 10.1007/s00262-018-2232-y. [Epub ahead of print]

PMID:
30159779
2.

The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes.

Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, Matsuba C, Takasumi Y, Ballesteros-Merino C, Fox BA, Barkhoudarian G, Kelly DF, Hoon DSB.

Clin Cancer Res. 2018 Sep 1;24(17):4126-4136. doi: 10.1158/1078-0432.CCR-17-2206. Epub 2018 Jul 3.

PMID:
30084836
3.

The Metastatic Microenvironment: Melanoma-Microglia Cross-Talk Promotes the Malignant Phenotype of Melanoma Cells.

Izraely S, Ben-Menachem S, Sagi-Assif O, Telerman A, Zubrilov I, Ashkenazi O, Meshel T, Maman S, Orozco JIJ, Salomon MP, Marzese DM, Pasmanik-Chor M, Pikarsky E, Ehrlich M, Hoon DSB, Witz IP.

Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31745. [Epub ahead of print]

PMID:
29992556
4.

Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers.

Graff-Baker AN, Orozco JIJ, Marzese DM, Salomon MP, Hoon DSB, Goldfarb M.

Ann Surg Oncol. 2018 Oct;25(10):3082-3087. doi: 10.1245/s10434-018-6582-7. Epub 2018 Jun 28.

PMID:
29956094
5.

KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.

Wang W, Lim KG, Feng M, Bao Y, Lee PL, Cai Y, Chen Y, Zhang H, Marzese D, Hoon DSB, Yu Q.

Mol Cancer Ther. 2018 Sep;17(9):1973-1983. doi: 10.1158/1535-7163.MCT-17-0802. Epub 2018 Jun 20.

PMID:
29925528
6.

Alternative splicing and cancer metastasis: prognostic and therapeutic applications.

Marzese DM, Manughian-Peter AO, Orozco JIJ, Hoon DSB.

Clin Exp Metastasis. 2018 May 29. doi: 10.1007/s10585-018-9905-y. [Epub ahead of print]

PMID:
29845349
7.

miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.

Li W, Yi J, Zheng X, Liu S, Fu W, Ren L, Li L, Hoon DSB, Wang J, Du G.

Clin Epigenetics. 2018 May 16;10:64. doi: 10.1186/s13148-018-0495-y. eCollection 2018.

8.

Distinct histone modifications denote early stress-induced drug tolerance in cancer.

Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H.

Oncotarget. 2017 Dec 24;9(9):8206-8222. doi: 10.18632/oncotarget.23654. eCollection 2018 Feb 2.

9.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

10.

ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis.

Izraely S, Ben-Menachem S, Sagi-Assif O, Meshel T, Marzese DM, Ohe S, Zubrilov I, Pasmanik-Chor M, Hoon DSB, Witz IP.

Oncotarget. 2017 Jul 5;8(44):75778-75796. doi: 10.18632/oncotarget.19018. eCollection 2017 Sep 29.

11.

Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.

Goh JY, Feng M, Wang W, Oguz G, Yatim SMJM, Lee PL, Bao Y, Lim TH, Wang P, Tam WL, Kodahl AR, Lyng MB, Sarma S, Lin SY, Lezhava A, Yap YS, Lim AST, Hoon DSB, Ditzel HJ, Lee SC, Tan EY, Yu Q.

Nat Med. 2017 Nov;23(11):1319-1330. doi: 10.1038/nm.4405. Epub 2017 Sep 25.

PMID:
28967919
12.

P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway.

Wang J, Hirose H, Du G, Chong K, Kiyohara E, Witz IP, Hoon DSB.

Cancer Lett. 2017 Oct 28;407:66-75. doi: 10.1016/j.canlet.2017.08.001. Epub 2017 Aug 10.

PMID:
28803992
13.

Hypomethylation of CNTFRα is associated with proliferation and poor prognosis in lower grade gliomas.

Fan K, Wang X, Zhang J, Ramos RI, Zhang H, Li C, Ye D, Kang J, Marzese DM, Hoon DSB, Hua W.

Sci Rep. 2017 Aug 1;7(1):7079. doi: 10.1038/s41598-017-07124-9.

14.

NADPH oxidase 5 (NOX5)-induced reactive oxygen signaling modulates normoxic HIF-1α and p27Kip1 expression in malignant melanoma and other human tumors.

Antony S, Jiang G, Wu Y, Meitzler JL, Makhlouf HR, Haines DC, Butcher D, Hoon DS, Ji J, Zhang Y, Juhasz A, Lu J, Liu H, Dahan I, Konate M, Roy KK, Doroshow JH.

Mol Carcinog. 2017 Dec;56(12):2643-2662. doi: 10.1002/mc.22708. Epub 2017 Aug 30.

15.

Emerging Utility of Urinary Cell-free Nucleic Acid Biomarkers for Prostate, Bladder, and Renal Cancers.

Lin SY, Linehan JA, Wilson TG, Hoon DSB.

Eur Urol Focus. 2017 Apr;3(2-3):265-272. doi: 10.1016/j.euf.2017.03.009. Epub 2017 Mar 31. Review.

PMID:
28753876
16.

The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas.

Ruiz R, Jahid S, Harris M, Marzese DM, Espitia F, Vasudeva P, Chen CF, de Feraudy S, Wu J, Gillen DL, Krasieva TB, Tromberg BJ, Pavan WJ, Hoon DS, Ganesan AK.

PLoS Genet. 2017 Jul 28;13(7):e1006913. doi: 10.1371/journal.pgen.1006913. eCollection 2017 Jul.

17.

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM.

N Engl J Med. 2017 Jun 8;376(23):2211-2222. doi: 10.1056/NEJMoa1613210.

18.

MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.

Bustos MA, Ono S, Marzese DM, Oyama T, Iida Y, Cheung G, Nelson N, Hsu SC, Yu Q, Hoon DSB.

J Invest Dermatol. 2017 Sep;137(9):1955-1964. doi: 10.1016/j.jid.2017.03.039. Epub 2017 May 16.

19.

CCR4 is a determinant of melanoma brain metastasis.

Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S, Bayry J, Marzese DM, Ohe S, Hoon DSB, Erez N, Witz IP.

Oncotarget. 2017 May 9;8(19):31079-31091. doi: 10.18632/oncotarget.16076.

20.

Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma.

Iida Y, Ciechanover A, Marzese DM, Hata K, Bustos M, Ono S, Wang J, Salomon MP, Tran K, Lam S, Hsu S, Nelson N, Kravtsova-Ivantsiv Y, Mills GB, Davies MA, Hoon DSB.

Clin Cancer Res. 2017 Aug 15;23(16):4831-4842. doi: 10.1158/1078-0432.CCR-17-0146. Epub 2017 Apr 7.

Supplemental Content

Support Center